Kindred Biosciences Inc (KIN) Receives $9.88 Average Target Price from Analysts

Shares of Kindred Biosciences Inc (NASDAQ:KIN) have been given an average recommendation of “Buy” by the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $9.88.

A number of research firms have commented on KIN. HC Wainwright set a $10.00 price objective on shares of Kindred Biosciences and gave the company a “buy” rating in a research note on Tuesday, December 5th. B. Riley set a $11.00 price objective on shares of Kindred Biosciences and gave the company a “buy” rating in a research note on Tuesday, December 5th. ValuEngine upgraded shares of Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research lowered shares of Kindred Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th.

Kindred Biosciences (KIN) traded up $0.10 during midday trading on Monday, reaching $8.15. 128,122 shares of the company’s stock were exchanged, compared to its average volume of 142,351. Kindred Biosciences has a one year low of $4.15 and a one year high of $9.65.

Kindred Biosciences (NASDAQ:KIN) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. equities research analysts anticipate that Kindred Biosciences will post -1.19 EPS for the current year.

Several large investors have recently modified their holdings of KIN. Dimensional Fund Advisors LP boosted its holdings in shares of Kindred Biosciences by 2.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,369,688 shares of the biopharmaceutical company’s stock valued at $9,656,000 after acquiring an additional 34,735 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Kindred Biosciences by 28.5% in the first quarter. Goldman Sachs Group Inc. now owns 22,336 shares of the biopharmaceutical company’s stock valued at $157,000 after acquiring an additional 4,954 shares in the last quarter. Trexquant Investment LP purchased a new stake in shares of Kindred Biosciences in the second quarter valued at about $120,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Kindred Biosciences in the second quarter valued at about $306,000. Finally, Rhumbline Advisers purchased a new stake in shares of Kindred Biosciences in the second quarter valued at about $197,000. 66.85% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://stocknewstimes.com/2017/12/14/kindred-biosciences-inc-kin-receives-9-88-average-target-price-from-analysts.html.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply